Kristina Goutsouliak is an Oncology physician. OpenAlex indexes 7 publications with 323 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2596 F Rd
Grand Junction, CO 815051443
Telephone
970-254-3180Provider last certified this registry record 16 Jul 2020.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20253 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
30.5%Aromatase Inhibitor24%Letrozole77%Exemestane23%Part D≥55 patientsAntimetabolite3.4%Hydroxyurea100%Part D<11 patients+ 1 more class in this area
Nervous system
26.7%Phenothiazine10.6%Prochlorperazine Maleate100%Part D≥50 patientsOpioid Agonist7.3%Tramadol Hcl46%Oxycodone Hcl37%Oxycodone-Acetaminophen18%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
18.6%Serotonin-3 Receptor Antagonist11.9%Ondansetron Hcl100%Part D≥57 patientsPotassium supplement3.5%Potassium Chloride100%Part D≥15 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers
Breast Cancer Research and Treatment
2022 - Towards personalized treatment for early stage HER2-positive breast cancer
Nature Reviews Clinical Oncology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”